Circular rna derived from rna viruses and related compositions and methods
AssigneesCZ Biohub SF, LLC, The Board of Trustees of the Leland Stanford Junior University
InventorsPeter Sarnow, Qian Cao
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions for reducing the proviral effect of a virus-derived circular RNA on a target cell through the use of an agent that blocks a proviral function of the virus-derived circular RNA. Also, provided herein are methods of treating a cytoplasmic or nuclear RNA viral infection in a subject and compositions to block a proviral effect of a virus-derived circular RNA or compositions that promote an antiviral effect of the virus-derived circular RNA.
Claims30
A method of reducing a proviral effect of a virus-derived circular RNA on a target cell, the method comprising:
- (a) identifying a virus-derived circular RNA having a proviral effect, wherein the virus-derived circular RNA is derived from a genome of an RNA virus;
- and
- (b) contacting the target cell with an agent that blocks a proviral function of the virus-derived circular RNA.
(canceled)
(canceled)
(canceled)
13-15. (canceled)
A method of promoting an innate immune response in a subject, the method comprising administering to the subject a virus-derived circular RNA derived from a genome of an RNA virus, wherein the virus-derived circular RNA promotes in the subject an innate immune response to the RNA virus.
A method of promoting an innate immune response in a subject, the method comprising administering to the subject an agent that blocks a function of a virus-derived circular RNA derived from a genome of an RNA virus and wherein the virus-derived circular RNA reduces in the subject an innate immune response to the RNA virus.
(canceled)
A method of treating an RNA viral infection in a subject, the method comprising:
- (a) detecting in a biological sample from the subject a virus-derived circular RNA, wherein the virus-derived circular RNA is derived from a genome of an RNA virus;
- and
- (b) administering to the subject a therapeutically effective amount of an antiviral agent.
(canceled)
A method of treating an RNA viral infection in a subject, comprising:
- (a) detecting in a biological sample from the subject a polypeptide translated from a virus-derived circular RNA, wherein the virus-derived circular RNA is derived from a genome of a cytoplasmic RNA virus;
- and
- (b) administering to the subject a therapeutically effective amount of an antiviral agent.
(canceled)
A nanoparticle comprising:
- (a) an agent that blocks a function of a virus-derived circular RNA;
- and
- (b) a polymer layer encapsulating the agent.
A vector encoding an siRNA, an shRNA, a RNA-targeting CRISPR-Cas system, or a small molecule that targets a virus-derived circular RNA, wherein the virus-derived circular RNA is derived from a genome of an RNA virus.
A nanoparticle comprising:
- (a) a vector encoding an siRNA, an shRNA, or a RNA-targeting CRISPR-Cas system that targets a virus-derived circular RNA, wherein the virus-derived circular RNA is derived from a genome of an RNA virus;
- and
- (b) a polymer layer encapsulating the vector.
A method of modulating an effect of a virus-derived circular RNA on one or more uninfected bystander cells, the method comprising contacting the one or more uninfected bystander cells with a therapeutically effective amount of an agent that blocks a proviral effect of the virus-derived circular RNA on the one or more uninfected bystander cells or an agent that promotes an antiviral effect of the virus-derived circular RNA in the one or more uninfected bystander cells.
Dependencies are inferred from the claim text.